Investigational drug · Phase 3
IBI3003
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma, Relapsed or Refractory Multiple Myeloma.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "IBI3003"
First trial start
2024
Jul 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI3003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI3003" as an intervention, largest first.
Fortvita Biologics (USA)Inc.Industry
NCT07336472 · 360 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2027
Drug: IBI3003 · For: Multiple Myeloma
Sites: Scottsdale, Arizona; Duarte, California; Irvine, California · 6 sites in all
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003Pivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07623798 · 255 participants (planned) · Start Jun 11, 2026 · Primary completion May 31, 2029
Drug: Pomalidomide Capsules; Bortezomib for Injection and 3 more · For: Relapsed or Refractory Multiple Myeloma
Sites: Shanghai, China
- A Open-Label Phase in Participants With Multiple MyelomaNot yet recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07764861 · 120 participants (planned) · Start Aug 15, 2026 · Primary completion Dec 31, 2026
Drug: Dexamethasone; IBI3003 and 2 more · For: Multiple Myeloma
Sites: Beijing, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06083207 · 116 participants (planned) · Start Jul 29, 2024 · Primary completion Oct 31, 2026
Drug: IBI3003 · For: Multiple Myeloma
Sites: Wollongong, Australia; Heidelberg, Australia; Melbourne, Australia · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.